

I hereby certify that this correspondence is
being deposited via the United States
Postal Service as first class mail in an
envelope addressed to: Assistant Commissioner
for Trademarks, 2900 Crystal Drive, Arlington,
Virginia 22202-3513, on 7-16-98
FELICE & LYNCH



BOX SEC/AM 1644

LUD 5253.5 DIV. - JEL/NDH

By Jani Kostopoulos

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Thierry BOON-FALLEUR et al.

Serial No. : 08/819,669

Filed : March 17, 1997

For : TUMOR REJECTION ANTIGEN PRECURSORS, TUMOR
REJECTION ANTIGENS AND USES THEREOF

Art Unit : 1644

Examiner : T. Cunningham

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

July 6, 1998

RECEIVED

15 1998

SUPPLEMENTAL RESPONSE

SIR:

Further to their amendment of June 9, 1998, applicants ask that this application be amended as follows:

IN THE SPECIFICATION

Please replace the paper copy of sequence information and computer readable form thereof with the attached materials.

REMARKS

At page 5, point 10 of the Office Action of March 17, 1998, the Examiner stated:

"If any originally disclosed MAGE-1 amino acid sequence has been modified or corrected the applicant is requested to notify the Examiner of the correction and date the correction was made."